Monte Rosa Therapeutics (GLUE) Retained Earnings (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Retained Earnings of -$521.7 million for Q1 2026, down 33.19% year-over-year from -$780.9 million in Q1 2025, and down 13532.53% quarter-over-quarter from -$3.8 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Retained Earnings (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$521.7 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 33.19% year-over-year to -$521.7 million; the TTM figure through Mar 2026 stood at -$521.7 million (down 33.19% YoY), while the FY2025 annual figure was -$3.8 million, down 14.03% from the prior year.
- Retained Earnings for Q1 2026 stood at -$521.7 million, down from -$3.8 million in the prior quarter.
- The five-year high for Retained Earnings was -$1.5 million in Q3 2023, with the low at -$521.7 million in Q1 2026.
- The 5-year median for Retained Earnings is -$3.4 million (2025), against an average of -$138.8 million.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 99.27% in 2023, then plunged 14445.12% in 2025.
- Monte Rosa Therapeutics' Retained Earnings stood at -$230.5 million in 2022, then jumped by 98.82% to -$2.7 million in 2023, then retreated by 23.2% to -$3.4 million in 2024, then decreased by 14.03% to -$3.8 million in 2025, then sank by 13532.53% to -$521.7 million in 2026.
- Business Quant data shows GLUE's Retained Earnings at -$521.7 million in Q1 2026, -$3.8 million in Q4 2025, and -$3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | -565.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -565.11 Mn |
| Mar 31, 2026 | -521.72 Mn |
| Dec 31, 2025 | -3.83 Mn |
| Sep 30, 2025 | -3.25 Mn |
| Jun 30, 2025 | -3.37 Mn |
| Mar 31, 2025 | -391.70 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Sep 30, 2024 | -2.32 Mn |
| Jun 30, 2024 | -428.20 Mn |
| Mar 31, 2024 | -2.69 Mn |
| Dec 31, 2023 | -2.72 Mn |
| Sep 30, 2023 | -1.46 Mn |
| Jun 30, 2023 | -297.75 Mn |
| Mar 31, 2023 | -262.60 Mn |
| Dec 31, 2022 | -230.54 Mn |
| Sep 30, 2022 | -199.75 Mn |
| Jun 30, 2022 | -2.46 Mn |
| Mar 31, 2022 | -2.13 Mn |
| Dec 31, 2021 | -2.02 Mn |
| Sep 30, 2021 | -1.95 Mn |